JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Jazz Pharmaceuticals (JAZZ) announced that the FDA has granted accelerated approval to its intravenously administered drug zanidatamab for certain patients with biliary tract cancer (BTC). The drug will be marketed under the trade name Ziihera.With this nod, Ziihera gets approved for use in previously treated adult patients with unresectable or metastatic HER2-positive BTC. The approval also makes this drug the first dual HER2-targeted bispecific antibody and chemotherapy-free therapy for treating BTC in th ...